These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 16856621

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
    Carosi G, Bruno R, Cariti G, Nasta P, Gulminetti R, Galli M, Angarano G, Verucchi G, Pontali E, Capetti A, Raise E, Ravasio V, Maida I, Iannacone C, Caputo A, Puoti M.
    Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
    [Abstract] [Full Text] [Related]

  • 23. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA, Valera-Bestard B, Arizcorreta-Yarza A, González-Serrano M, Torre-Cisneros J, Santos I, Vergara S, Gutiérrez-Valencia A, Girón-González JA, Macías J, López-Cortés LF, Pineda JA.
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M, PRESCO Study Group.
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 28. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Hepatol; 2007 Mar 02; 46(3):403-10. PubMed ID: 17126448
    [Abstract] [Full Text] [Related]

  • 29. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V, Núñez M, Camino N, Maida I, Barreiro P, Romero M, Martin-Carbonero L, Garcia-Samaniego J, González-Lahoz J.
    Antivir Ther; 2004 Aug 02; 9(4):505-9. PubMed ID: 15456081
    [Abstract] [Full Text] [Related]

  • 30. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J.
    J Hepatol; 2005 Jul 02; 43(1):53-9. PubMed ID: 15876467
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, Berenguer J, Montes-Ramírez M, Clotet B, CORAL-1 study group.
    J Viral Hepat; 2007 Oct 02; 14(10):704-13. PubMed ID: 17875005
    [Abstract] [Full Text] [Related]

  • 32. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.
    Lee SS, Ferenci P.
    Antivir Ther; 2008 Oct 02; 13 Suppl 1():9-16. PubMed ID: 18432158
    [Abstract] [Full Text] [Related]

  • 33. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M, Morlat P, Bonnet F, Rambeloarisoa J, Bernard N, Lacoste D, Bonarek M, Trimoulet P, Ramanampamonjy R, Lafon ME, Dramé M, Beylot J.
    Rev Med Interne; 2005 Apr 02; 26(4):280-7. PubMed ID: 15820563
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
    Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D.
    Am J Gastroenterol; 2011 Mar 02; 106(3):452-8. PubMed ID: 21063395
    [Abstract] [Full Text] [Related]

  • 35. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
    Ballesteros AL, Franco S, Fuster D, Planas R, Martínez MA, Acosta L, Sirera G, Salas A, Tor J, Rey-Joly C, Clotet B, Tural C.
    AIDS; 2004 Jan 02; 18(1):59-66. PubMed ID: 15090830
    [Abstract] [Full Text] [Related]

  • 36. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
    Lopez-Cortes LF, Valera-Bestard B, Gutierrez-Valencia A, Ruiz-Valderas R, Jimenez L, Arizcorreta A, Terrón A, Viciana P.
    Clin Pharmacol Ther; 2008 Nov 02; 84(5):573-80. PubMed ID: 18596682
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF, Sun HQ, Huang Q, Wang JR, Zhang XX, Liu XN, Ma Q, Lu HZ.
    Haemophilia; 2010 May 02; 16(3):502-7. PubMed ID: 20028427
    [Abstract] [Full Text] [Related]

  • 38. Hepatitis C virus genotype 5: prospective evaluation of peginterferon/ribavirin treatment efficacy and predictive value of on-treatment virological responses for sustained virological response.
    Papastergiou V, Skorda L, Lisgos P, Stampori M, Ntetskas G, Papakonstantinou L, Prodromidou K, Karatapanis S.
    J Clin Gastroenterol; 2014 Feb 02; 48(2):160-5. PubMed ID: 24100748
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of the therapeutic response of hepatitis C in coinfected patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the Eastern Brazilian Amazon.
    Amaral Ido S, Móia Lde J, Barbosa MS, Demachki S, Araújo MT, Soares Mdo C.
    Rev Soc Bras Med Trop; 2013 Feb 02; 46(1):20-3. PubMed ID: 23563820
    [Abstract] [Full Text] [Related]

  • 40. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.
    Merchante N, de los Santos-Gil I, Merino D, González-Serrano M, Mira JA, Sanz-Sanz J, Fernández-Fuertes E, Ruiz-Morales J, del Valle J, Macías J, Moro A, Pineda JA.
    J Hepatol; 2009 Apr 02; 50(4):684-92. PubMed ID: 19231001
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.